newsfilter
← Latest News
GlobeNewswire·

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

  • Chemomab Therapeutics announced Q1 2026 financial results & clinical updates on May 14, 2026, highlighting new data on nebokitug for primary sclerosing cholangitis (PSC).
  • New analyses from the Phase 2 SPRING trial presented at Digestive Disease Week® 2026 & upcoming EASL 2026 congress confirm nebokitug's disease-modifying potential & suggest benefits for patients with co-existing inflammatory bowel disease (IBD).
  • AI-driven proteomic analysis successfully distinguished PSC patients showing combined improvements in fibrosis measures following nebokitug treatment.
  • Nebokitug demonstrated dose-dependent reductions in gene expression programs related to fibrosis, macrophage activation, & immune activation in PSC patients.
  • Treatment with nebokitug modulated inflammatory & tissue-remodeling signatures relevant to both PSC & IBD, with 62% of trial patients having concomitant IBD.
  • Cash, cash equivalents, & short-term bank deposits totaled $8.0 million as of March 31, 2026, providing a runway through Q1 2027.
  • Research & development expenses decreased to $0.9 million in Q1 2026 from $2.5 million in Q1 2025 due to winding down Phase 2 SPRING trial activities.
  • The company reported a net loss of $1.8 million for Q1 2026, compared to $3.3 million in the prior year period.
  • Chemomab & the FDA have aligned on the design for a Phase 3 registration trial of nebokitug in PSC.
  • Nebokitug holds Orphan Drug & Fast Track designations from the FDA & EMA for PSC, with additional Orphan Drug designations for systemic sclerosis.